$3.40
-0.36-9.57%
Last update: Nov 5, 2:19 PM
Immuneering Corp (IMRX) Stock Price, Quote, News & History
IMRXNASDAQ
Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, manageable safety, and key trial milestones expected in 2026.
You can purchase shares of Immuneering (NASDAQ:IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Immuneering has a consensus price target of $15.13.
The stock price for Immuneering (NASDAQ: IMRX) is $3.4 last updated November 5, 2026 at 2:19 PM EST.
There are no upcoming dividends for Immuneering.
Immuneering does not have any upcoming earnings scheduled.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug...
